Staging Chronic Liver Disease in Adults
Use a tiered noninvasive approach starting with FIB-4 score in all patients, followed by imaging-based liver stiffness measurement (preferably MRE, or TE if unavailable) for those with indeterminate or high-risk results to accurately stage fibrosis and avoid unnecessary liver biopsies. 1
Initial Risk Stratification: Blood-Based Biomarkers
Begin with FIB-4 (Fibrosis-4 Index) as your first-line screening tool—it outperforms APRI (aspartate aminotransferase-to-platelet ratio index) for detecting both advanced fibrosis (F3-4) and cirrhosis (F4) 2. The FIB-4 thresholds are:
- FIB-4 <1.45: Low risk—rules out advanced fibrosis with high confidence; annual monitoring sufficient
- FIB-4 1.45-3.25: Indeterminate risk—proceed to second-line testing
- FIB-4 >3.25: High risk—proceed to second-line testing and consider specialist referral
This initial blood-based approach provides only small-to-moderate changes in pretest probability (likelihood ratios 1.66-7.15), which is why indeterminate and high-risk patients require confirmatory imaging 2.
Second-Line Testing: Imaging-Based Liver Stiffness Measurement
For patients with FIB-4 ≥1.45, proceed to imaging-based noninvasive liver disease assessment (NILDA):
Preferred hierarchy based on accuracy 1:
Magnetic Resonance Elastography (MRE): Most accurate method across all fibrosis stages
- Sensitivities: 70-100% for F3-4,60-100% for F4
- Specificities: 74-100% for F3-4,67-99% for F4
Transient Elastography (TE/Vibration-Controlled TE): Most widely available, largest evidence base
- Similar accuracy to MRE but slightly lower
- More accessible in most clinical settings
Shear Wave Elastography (SWE/ARFI): Acceptable accuracy, ultrasound-based alternative
Critical caveat: Liver stiffness values can be falsely elevated by active hepatic inflammation, recent food intake, vascular congestion, obstructive cholestasis, and active alcohol use 1, 3. In MetALD patients, interpret elastography cautiously during periods of alcohol consumption as stiffness may transiently increase independent of fibrosis 3.
Accuracy by Fibrosis Stage
Imaging-based NILDA accuracy increases progressively from earlier to later fibrosis stages 1:
- F2-4 (significant fibrosis): Sensitivity 51-95%, specificity 36-100%
- F3-4 (advanced fibrosis): Sensitivity 70-100%, specificity 74-100%
- F4 (cirrhosis): Sensitivity 60-100%, specificity 67-99%
This means these tests are most reliable for ruling in or ruling out cirrhosis and advanced fibrosis, and less definitive for intermediate stages.
Disease-Specific Considerations
Cutoff values vary by etiology 1—use disease-specific thresholds for:
- Viral hepatitis (HBV, HCV)
- NAFLD/MASLD
- Alcohol-associated liver disease
- HIV coinfection
The 2023 nomenclature now classifies steatotic liver disease into MASLD, MetALD (metabolic dysfunction + alcohol 140-350 g/week in women, 210-420 g/week in men), and alcohol-associated liver disease 3.
When Imaging-Based NILDA Outperforms Blood Tests
Imaging-based NILDA significantly outperforms blood-based biomarkers for detecting F3-4 and F4 1. Use imaging rather than relying solely on FIB-4 or APRI when:
- Staging advanced fibrosis or cirrhosis
- Making treatment decisions
- Determining need for hepatocellular carcinoma surveillance
- Assessing varices screening needs
Combination Testing Strategy
The Enhanced Liver Fibrosis (ELF) test can serve as an alternative second-line test to elastography 3, though imaging-based methods generally provide superior accuracy for advanced fibrosis detection 1.
Avoid combining multiple blood tests—limited data supports this approach, and it doesn't improve accuracy meaningfully 2.
Monitoring and Reassessment
- Low-risk patients (FIB-4 <1.45): Reassess annually with FIB-4 3
- Patients with fibrosis: Repeat elastography every 6-12 months depending on disease activity and treatment response
- After treatment initiation: LSM may drop rapidly with inflammation resolution (e.g., antiviral therapy, alcohol cessation) before actual fibrosis regression—this does not reflect immediate fibrosis improvement 1
Pediatric Population
The same imaging-based NILDA techniques appear equally accurate in children as in adults, though standardization remains limited 1.